TRD Societal Cost Can Sway US Payer On VNS Coverage Decision
Executive Summary
LivaNova is counting on CMS paying more than lip service to the value-based agenda as it assesses coverage decisions for Vagus Nerve Stimulation (VNS) for the treatment of resistant depression over the coming months. In many ways it is a test for both parties.
You may also be interested in...
Limited Medicare Coverage Policy Proposed For Depression VNS Treatment
The US Centers for Medicare and Medicaid Services' proposed national coverage policy for vagus nerve stimulation for depression would allow coverage only in a randomized controlled trial, stipulating multiple caveats on patient choice and endpoints. Manufacturer LivaNova says it is preparing to launch a qualifying study.
LivaNova Builds Strategic Base And Commercial Case To Silence Skeptics
Medical innovator LivaNova has a new stated focus: it won’t go outside the head and the heart when it comes to potential M&A and technology development projects. It has set out short- and longer-term solutions to boost sales and/or profitability in its neuromodulation and cardio franchises. What is certain is that eight months into his tenure as CEO, Damien McDonald is stamping his imprint all over LivaNova.
UK Government Promise For 2021: No Halting The Advance Of Healthtech Innovation Adoption
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
Need a specific report? 1000+ reports available
Buy Reports